ArticleThe Journal of clinical and aesthetic dermatology2010
The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators.
Article in The Journal of clinical and aesthetic dermatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Dissecting Cellulitis of the Scalp: Linking Pathogenesis to Therapy.Biomedicines · 2026Review
- CD271 orchestrates skin structure, differentiation, and inflammation via PI3K/Akt and PKCα/ERK pathways.Cell death & disease · 2025Article
- The impact of innate immunity and epigenetics in the pathogenesis of hidradenitis suppurativa.Frontiers in immunology · 2025Review
- Bayesian model and selection signature analyses reveal risk factors for canine atopic dermatitis.Communications biology · 2022Article
- Oxy210, a Semi-Synthetic Oxysterol, Exerts Anti-Inflammatory Effects in Macrophages via Inhibition of Toll-like Receptor (TLR) 4 and TLR2 Signaling and Modulation of Macrophage Polarization.International journal of molecular sciences · 2022Article
- The Role of Herbal Medicine in the Treatment of Acne Vulgaris: A Systematic Review of Clinical Trials.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Soluble Factors and Receptors Involved in Skin Innate Immunity-What Do We Know So Far?Biomedicines · 2021Review
- Recent Advances Regarding the Therapeutic Potential of Adapalene.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Omega-3 Versus Omega-6 Polyunsaturated Fatty Acids in the Prevention and Treatment of Inflammatory Skin Diseases.International journal of molecular sciences · 2020Review
- Suppression ofInternational journal of molecular sciences · 2019Article
- The efficacy of glycolic acid, salicylic acid, gluconolactone, and licochalcone A combined with 0.1% adapalene vs adapalene monotherapy in mild-to-moderate acne vulgaris: a double-blinded within-person comparative study.Clinical, cosmetic and investigational dermatology · 2019Article
- Epidermal Growth Factor Attenuated the Expression of Inflammatory Cytokines in Human Epidermal Keratinocyte Exposed toAnnals of dermatology · 2018Article
- Differential regulation of surface receptor expression, proliferation, and apoptosis in HaCaT cells stimulated with interferon-γ, interleukin-4, tumor necrosis factor-α, or muramyl dipeptide.International journal of immunopathology and pharmacology · 2017Article
- TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma.Oncology letters · 2016Article
- Association between Toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma.Biomedical reports · 2016Article
- The nucleic acid scavenger polyamidoamine third-generation dendrimer inhibits fibroblast activation and granulation tissue contraction.Plastic and reconstructive surgery · 2014Article
- Neurosyphilis in a man with human immunodeficiency virus.The Journal of clinical and aesthetic dermatology · 2014Article
- Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.Experimental dermatology · 2014Article
- Dramatic response to oral zinc in a case of subacute form of generalized pustular psoriasis.Indian journal of dermatology · 2012Article
- Pattern recognition receptors in immune disorders affecting the skin.Journal of innate immunity · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toll-like receptors are a group of glycoproteins located mostly in cellular membranes, capable of recognizing certain molecules in exogenous microorganisms and initiating immune responses against them through the activation of several intracellular signaling pathways. Toll-like receptors can be stimulated when an inflammatory reaction is needed for the treatment of conditions, such as viral infections or skin cancer, or can be inhibited when a reduction of inflammation is necessary for the treatment of conditions, such as rheumatoid arthritis, systemic lupus erythematosus, and septic shock. In the human skin, keratinocytes and Langerhans cells are known to express these receptors. Skin conditions where Toll-like receptors are known to be upregulated include acne, psoriasis, atopic dermatitis, syphilis, leprosy, Staphylococcus aureus infections, candidiasis, and herpes simplex and varicella zoster infections. Besides imiquimod, which is the most successful and more studied topical Toll-like receptor-modulating agent to date, other topical agents, such as nicotinamide, all-trans retinoic acid, adapalene, zinc, and sodium tosylchloramide, have also been found to exert some of their action through Toll-like receptors. Recent topical agents, including CBT-SL5 and CpG-ODN, are being evaluated for the treatment of inflammatory acne and skin cancer, respectively, and have demonstrated to be effective in the treatment of those conditions.
Identifiers
20877521PMC2945844W1477108763What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.